Cogent Biosciences, Inc. Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

株式のランク #3254
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
株価
$31.37
時価総額
$5.44B
変化（1日）
4.54%
変化（1年）
93.42%
国
US
取引 Cogent Biosciences, Inc. (COGT)

カテゴリー

Healthcare
Cogent Biosciences, Inc.（COGT）の株式分割履歴
Cogent Biosciences, Inc.株（シンボル：COGT）は合計で1回の株式分割を実施しました。
最新の株式分割はNov 09, 2020に行われました。
Nov 09, 2020より前に購入されたCOGT株は、現在0.25COGT株に相当します。
株式分割一覧
年 株式分割 分割比率 累積分割比率
2020-11-09 1:4 x0.25 x0.25
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL